Open labelled, non randomized study to evaluate the effects of Artemisinin based Combined Therapies(ACTs) on schistosomiasis since Praziquantel (PZQ) which is presently the drug of choice for treating Schistosomiasis (STS), is ineffective on immature stages and there is known parasite resistance. ACTs when combined with PZQ, targeting different stages of the life cycle has shown some effectivity.
Study population included all subjects in study area who signed a written Informed Consent Form diagnosed with Malaria- STS co-infection. Those excluded were treated with PZQ prior 6 weeks, have drug intolerance or pregnant. At Inclusion, Basic Demographic data was recorded and urine samples analysed. During the follow up visits, urine samples were collected on D28 and D42 (6 weeks post treatment). Post treatment assessment was done on urine samples collected on at least two consecutive days and at the end of follow up, all subjects were treated with a single dose pf PZQ (40 mg/kg) as recommended by WHO.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
54
Subjects received artesunate-pyronaridine according to their body weight once per day for three days.
subjects received artemether-lumefantrine according to their body weight twice per day for three days.
Subject received a single dose of artefenomel-ferroquine according to their body weight
Centre de Recherches Medicales de Lambarene
Lambaréné, Gabon
Egg Reduction Rate (ERR)
Evaluate ERR conferred by ACTs as treatment of infection with Schistosoma hematobia
Time frame: Day 28
Egg Reduction Rate (ERR)
Evaluate ERR conferred by ACTs as treatment of infection with Schistosoma hematobia
Time frame: Day 42
Cure Rate (CR)
CR of ACTs on Schistosoma haematobia
Time frame: Day 28
Cure Rate (CR)
CR of ACTs on Schistosoma haematobia
Time frame: Day 42
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.